|
IMPROVE
Irbesartan in the Management of Proteinuric patients at high risk for Vascular Events
Ongoing trial
 |
Author(s) |
Bakris GL, Ruilope L, Locatelli F, Ptaszynska A, Pieske B, Raz I, Voors AA, Dechamplain J, Weber MA |
 |
Title(s) |
Rationale and design of a study to evaluate management of proteinuria in patients at high risk for vascular events: the IMPROVE trial |
|
Reference(s) |
J Hum Hypertens 2006;20:693–700 |
|
Disease |
Hypertension, renal failure |
|
Purpose |
To determine whether the combination therapy of irbesartan and the ACE inhibitor ramipril is more effective than ramipril alone in reducing urinary albumin excretion rate in patients at high cardiovascular risk with hypertension and proteinuria or microalbuminuria |
|
Study design |
Randomised, double-blind, placebo-controlled, parallel-group |
|
Follow-up |
20 weeks |
|
Patients |
407 patients, aged ≥ 55 years, with BP > 140/90 mm Hg and albumin excretion rate 20–700 μg/min, receiving treatment with an ACE inhibitor, at a dose equivalent to 5 mg or more of ramipril, for minimum 2 months |
|
Treatment regimen |
Ramipril, 10 mg/day, plus placebo, or ramipril, 10 mg/day, plus irbesartan, 150–300 mg/day |
|
Results |
Not yet available |
|
|
|
